Does the media favor ORKA or VTRS?

In the previous week, Viatris had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 4 mentions for Viatris and 2 mentions for Oruka Therapeutics. Viatris' average media sentiment score of 0.72 beat Oruka Therapeutics' score of 0.25 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ORKA or ASND?

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 2 mentions for Oruka Therapeutics. Ascendis Pharma A/S's average media sentiment score of 0.54 beat Oruka Therapeutics' score of 0.25 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oruka Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GMAB or ORKA?

In the previous week, Genmab A/S had 3 more articles in the media than Oruka Therapeutics. MarketBeat recorded 5 mentions for Genmab A/S and 2 mentions for Oruka Therapeutics. Genmab A/S's average media sentiment score of 0.69 beat Oruka Therapeutics' score of 0.25 indicating that Genmab A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BBIO or ORKA?

In the previous week, BridgeBio Pharma had 6 more articles in the media than Oruka Therapeutics. MarketBeat recorded 8 mentions for BridgeBio Pharma and 2 mentions for Oruka Therapeutics. BridgeBio Pharma's average media sentiment score of 0.63 beat Oruka Therapeutics' score of 0.25 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RDY or ORKA?

Oruka Therapeutics has a consensus target price of $134.30, indicating a potential upside of 57.61%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Oruka Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.82

Oruka Therapeutics (ORKA) Competitors

$85.21 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$82.00 -3.21 (-3.77%)

As of 07/2/2026 06:55 PM Eastern

Compare

ORKA vs. VTRS, ASND, GMAB, BBIO, and RDY

Should you buy Oruka Therapeutics stock or one of its competitors? MarketBeat compares Oruka Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oruka Therapeutics include Viatris (VTRS), Ascendis Pharma A/S (ASND), Genmab A/S (GMAB), BridgeBio Pharma (BBIO), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.

How does Oruka Therapeutics compare to Viatris?

Oruka Therapeutics (NASDAQ:ORKA) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Oruka Therapeutics has a beta of -0.35, suggesting that its share price is 135% less volatile than the broader market. Comparatively, Viatris has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

In the previous week, Viatris had 2 more articles in the media than Oruka Therapeutics. MarketBeat recorded 4 mentions for Viatris and 2 mentions for Oruka Therapeutics. Viatris' average media sentiment score of 0.72 beat Oruka Therapeutics' score of 0.25 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Viatris	-2.04%	19.04%	7.62%

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oruka Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Viatris	$14.30B	1.36	-$3.51B	-$0.26	N/A

Oruka Therapeutics presently has a consensus target price of $134.30, suggesting a potential upside of 57.61%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 4.79%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Oruka Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Viatris beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Oruka Therapeutics (NASDAQ:ORKA) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Oruka Therapeutics currently has a consensus price target of $134.30, suggesting a potential upside of 57.61%. Ascendis Pharma A/S has a consensus price target of $295.39, suggesting a potential upside of 7.61%. Given Oruka Therapeutics' higher possible upside, equities analysts clearly believe Oruka Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Oruka Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
Ascendis Pharma A/S	$865.78M	19.78	-$258M	$8.67	31.66

56.4% of Oruka Therapeutics shares are held by institutional investors. 23.5% of Oruka Therapeutics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Ascendis Pharma A/S had 5 more articles in the media than Oruka Therapeutics. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 2 mentions for Oruka Therapeutics. Ascendis Pharma A/S's average media sentiment score of 0.54 beat Oruka Therapeutics' score of 0.25 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Oruka Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Oruka Therapeutics has a beta of -0.35, meaning that its stock price is 135% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

Summary

Ascendis Pharma A/S beats Oruka Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Genmab A/S had 3 more articles in the media than Oruka Therapeutics. MarketBeat recorded 5 mentions for Genmab A/S and 2 mentions for Oruka Therapeutics. Genmab A/S's average media sentiment score of 0.69 beat Oruka Therapeutics' score of 0.25 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Genmab A/S currently has a consensus target price of $38.21, suggesting a potential upside of 34.04%. Oruka Therapeutics has a consensus target price of $134.30, suggesting a potential upside of 57.61%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Genmab A/S has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, suggesting that its stock price is 135% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.78	$963M	$1.32	21.60
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Genmab A/S has a net margin of 21.05% compared to Oruka Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	21.05%	15.34%	8.94%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Summary

Genmab A/S beats Oruka Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Oruka Therapeutics compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

BridgeBio Pharma has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, indicating that its stock price is 135% less volatile than the broader market.

In the previous week, BridgeBio Pharma had 6 more articles in the media than Oruka Therapeutics. MarketBeat recorded 8 mentions for BridgeBio Pharma and 2 mentions for Oruka Therapeutics. BridgeBio Pharma's average media sentiment score of 0.63 beat Oruka Therapeutics' score of 0.25 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oruka Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. Oruka Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	30.11	-$724.93M	-$3.74	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Oruka Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Oruka Therapeutics	N/A	-26.16%	-25.00%

BridgeBio Pharma presently has a consensus target price of $92.90, indicating a potential upside of 20.35%. Oruka Therapeutics has a consensus target price of $134.30, indicating a potential upside of 57.61%. Given Oruka Therapeutics' higher probable upside, analysts plainly believe Oruka Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BridgeBio Pharma beats Oruka Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Oruka Therapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Oruka Therapeutics (NASDAQ:ORKA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Dr. Reddy's Laboratories has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.35, suggesting that its stock price is 135% less volatile than the broader market.

Oruka Therapeutics has a consensus target price of $134.30, indicating a potential upside of 57.61%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Oruka Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 23.5% of Oruka Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Oruka Therapeutics had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 2 mentions for Oruka Therapeutics and 0 mentions for Dr. Reddy's Laboratories. Oruka Therapeutics' average media sentiment score of 0.25 beat Dr. Reddy's Laboratories' score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Dr. Reddy's Laboratories	Neutral
Oruka Therapeutics	Neutral

Dr. Reddy's Laboratories has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.35	$456M	$0.58	24.81
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Oruka Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Oruka Therapeutics	N/A	-26.16%	-25.00%

Summary

Dr. Reddy's Laboratories beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Oruka Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORKA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORKA vs. The Competition

Export

Metric	Oruka Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.14B	$3.10B	$7.18B	$12.47B
Dividend Yield	N/A	2.05%	2.67%	6.51%
P/E Ratio	-43.92	20.06	28.02	24.70
Price / Sales	N/A	357.08	534.82	99.69
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	8.79	4.32	10.96	6.46
Net Income	-$105.43M	$64.45M	$3.57B	$337.01M
7 Day Performance	-5.95%	2.97%	2.12%	1.69%
1 Month Performance	41.69%	6.83%	5.25%	3.81%
1 Year Performance	576.54%	29.07%	33.29%	23.90%

Oruka Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORKA Oruka Therapeutics	3.1357 of 5 stars	$85.21 flat	$134.30 +57.6%	+576.5%	$5.14B	N/A	N/A	N/A	Analyst Downgrade Gap Up High Trading Volume
VTRS Viatris	2.7838 of 5 stars	$16.33 +1.6%	$17.50 +7.2%	+80.5%	$18.71B	$14.56B	N/A	30,000	Gap Down
ASND Ascendis Pharma A/S	4.1402 of 5 stars	$260.75 -0.3%	$295.39 +13.3%	+57.7%	$16.32B	$814.57M	30.08	1,189	Analyst Upgrade High Trading Volume
GMAB Genmab A/S	4.7837 of 5 stars	$26.11 -0.1%	$37.93 +45.3%	+39.7%	$16.30B	$3.90B	19.78	3,029	Analyst Forecast
BBIO BridgeBio Pharma	2.7882 of 5 stars	$70.24 +0.8%	$92.90 +32.3%	+76.6%	$13.65B	$502.08M	N/A	400	Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORKA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oruka Therapeutics (ORKA) Competitors

ORKA vs. VTRS, ASND, GMAB, BBIO, and RDY

How does Oruka Therapeutics compare to Viatris?

Summary

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Oruka Therapeutics compare to Genmab A/S?

Summary

How does Oruka Therapeutics compare to BridgeBio Pharma?

Summary

How does Oruka Therapeutics compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oruka Therapeutics (ORKA) Competitors

ORKA vs. VTRS, ASND, GMAB, BBIO, and RDY

How does Oruka Therapeutics compare to Viatris?

Which has more risk and volatility, ORKA or VTRS?

Does the media favor ORKA or VTRS?

Is ORKA or VTRS more profitable?

Do institutionals & insiders hold more shares of ORKA or VTRS?

Which has preferable earnings & valuation, ORKA or VTRS?

Do analysts recommend ORKA or VTRS?

Summary

How does Oruka Therapeutics compare to Ascendis Pharma A/S?

Do analysts rate ORKA or ASND?

Which has preferable valuation and earnings, ORKA or ASND?

Do institutionals and insiders have more ownership in ORKA or ASND?

Does the media prefer ORKA or ASND?

Is ORKA or ASND more profitable?

Which has more risk and volatility, ORKA or ASND?

Summary

How does Oruka Therapeutics compare to Genmab A/S?

Does the media prefer GMAB or ORKA?

Do institutionals and insiders hold more shares of GMAB or ORKA?

Do analysts rate GMAB or ORKA?

Which has more volatility & risk, GMAB or ORKA?

Which has stronger valuation and earnings, GMAB or ORKA?

Is GMAB or ORKA more profitable?

Summary

How does Oruka Therapeutics compare to BridgeBio Pharma?

Which has more volatility & risk, BBIO or ORKA?

Does the media favor BBIO or ORKA?

Which has better earnings and valuation, BBIO or ORKA?

Is BBIO or ORKA more profitable?

Do analysts prefer BBIO or ORKA?

Do institutionals & insiders believe in BBIO or ORKA?

Summary

How does Oruka Therapeutics compare to Dr. Reddy's Laboratories?

Which has more risk and volatility, RDY or ORKA?

Do analysts recommend RDY or ORKA?

Do institutionals & insiders believe in RDY or ORKA?

Does the media favor RDY or ORKA?

Which has preferable earnings and valuation, RDY or ORKA?

Is RDY or ORKA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA vs. The Competition

Oruka Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools